Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000322 · ClinicalTrials.gov registry record · Phase 2
Tyrosine for Methamphetamine Dependence - 1
A Phase 2 study of Amphetamine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT00000322: Completed Phase 2 study of Amphetamine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
NCT00000322 is a Phase 2 study of Amphetamine-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 89 participants, above the 74-participant average among 5 other Amphetamine-Related Disorders trials with a reported enrollment target (20% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000322, a Phase 2 study of Amphetamine-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions. Examine effect of tyrosine on abstinence, retention in treatment, and craving."
Conditions Studied
Interventions
- BEHAVIORAL Tyrosine
Study Locations (1)
California
- Haight Ashbury Free Clinics - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 1997-04 |
| Est. Completion | 2001-12 |
| Phase | Phase 2 |
What the finished NCT00000322 record still lists
NCT00000322 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, above the 74-participant average among 5 other Amphetamine-Related Disorders trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Amphetamine-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Tyrosine is the first listed.
NCT00000322 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00000322 about?
NCT00000322 is a clinical study titled "Tyrosine for Methamphetamine Dependence - 1". The purpose of this study is to evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions. Examine effect of tyrosine on abstinence, retention in treatment, and craving."
What is the current status of trial NCT00000322?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 1997-04. Estimated completion is 2001-12.
What conditions does trial NCT00000322 study?
This clinical trial studies the following conditions: Amphetamine-Related Disorders.
What interventions are being tested in trial NCT00000322?
The interventions under investigation include: Tyrosine (BEHAVIORAL).
Who is sponsoring clinical trial NCT00000322?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000322 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amphetamine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men
COMPLETED · Phase 2
-
Bupropion for the Treatment of Methamphetamine Dependence - 1
COMPLETED · Phase 2
-
Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)
COMPLETED · Phase 2
-
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
RECRUITING · Phase 1
-
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia